• / Free eNewsletters & Magazine
  • / My Account
Home>Funds>Old Mutual 2021-2030 Conservative A

Old Mutual 2021-2030 Conservative A

  1. Immune Pharmaceuticals Commences Patient Screening For Bertilimumab Phase II Clinical Trial In Bullous Pemphigoid, A Rare Auto-Immune Disease Of The Skin

    Immune Pharmaceuticals Commences Patient Screening For Bertilimumab Phase II Clinical Trial In Bullous Pemphigoid, A Rare Auto-Immune Disease Of The Skin

  2. Cielo - 17.9% Increase in Financial Volume and Net Income of R$797 Million in 2Q14

    Cielo - 17.9% Increase in Financial Volume and Net Income of R$797 Million in 2Q14

  3. Cerro Grande Mining Corporation Announces it is Pursuing a Listing on the TSX Venture Exchange

    Cerro Grande Mining Corporation Announces it is Pursuing a Listing on the TSX Venture Exchange

  4. OTC Markets Group Welcomes Abattis Bioceuticals to OTCQX ®

    OTC Markets Group Welcomes Abattis Bioceuticals to OTCQX ®

  5. Delta Galil Reports Record Results for Second Quarter of 2014

    Delta Galil Reports Record Results for Second Quarter of 2014

  6. Destiny Media Technologies Provides Development Update for New Disruptive Clipstream® Products and Services

    Destiny Media Technologies Provides Development Update for New Disruptive Clipstream® Products and Services

  7. Technip’s Second Quarter 2014 Results

    Technip’s Second Quarter 2014 Results

  8. Innovative Collaboration To Increase Awareness Of Bullous Pemphigoid, A Rare Autoimmune Disease Of The Skin

    Innovative Collaboration To Increase Awareness Of Bullous Pemphigoid, A Rare Autoimmune Disease Of The Skin

  9. TAG Oil Begins Drilling Waitangi Valley-1 Unconventional Exploration Well

    TAG Oil Begins Drilling Waitangi Valley-1 Unconventional Exploration Well

  10. International Energy & Mineral Resources (Hong Kong) litigation developments

    International Energy & Mineral Resources (Hong Kong) litigation developments

12345
Upcoming Events
Conferences
Webinars

©2014 Morningstar Advisor. All right reserved.